Cost Insights: A Comparative Analysis of Viatris Inc. and Walgreens Boots Alliance, Inc.

In the ever-evolving landscape of the pharmaceutical and retail sectors, understanding cost structures is crucial. Viatris Inc. and Walgreens Boots Alliance, Inc. have been pivotal players, each with unique financial trajectories. From 2014 to 2023, Walgreens Boots Alliance consistently reported higher costs of revenue, peaking at approximately $112 billion in 2023, a 104% increase from 2014. In contrast, Viatris Inc. saw a significant rise in 2021, with costs reaching around $12 billion, marking a 204% increase from 2014. However, by 2023, Viatris's costs slightly declined to about $9 billion. This data highlights Walgreens' robust growth and Viatris's fluctuating expenses, reflecting strategic shifts and market dynamics. Notably, 2024 data for Viatris is missing, indicating potential reporting delays or strategic changes. Such insights are invaluable for investors and analysts navigating these industries.